Johannes Lammer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johannes Lammer has a total of 194 co-authors. Here are the top co-authors by number of shared publications:
E Pilger
5 shared publicationsF Flückiger
4 shared publicationsG E Klein
4 shared publications- M. Funovics
Department of Radiology, Medical University Vienna, Vienna, Austria
4 shared publications - M. Schoder
Abteilung für Angiographie und Interventionelle Radiologie Univ. Klinik für Radiodiagnostik, Wien, Germany
4 shared publications F Wolf
3 shared publications
Latest Publications
- 8 June 2020
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 27 (4) , 623-625
Commentary: Bioresorbable Drug-Eluting Scaffold for Peripheral Artery Disease: The Best of Two Worlds or Unnecessary?
- 8 June 2020
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 27 (4) , 623-625
Commentary: Bioresorbable Drug-Eluting Scaffold for Peripheral Artery Disease: The Best of Two Worlds or Unnecessary?
- Open Access
- 10 May 2020
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 43 (7) , 1099
Reply to: Commentary to Josef Tacke, et al. The Randomized Freeway Stent Study: Drug-Eluting Balloons Outperform Standard Balloon Angioplasty for Postdilatation of Nitinol Stents in the SFA and PI Segment
- 10 May 2020
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 43 (7) , 1099
Open AccessReply to: Commentary to Josef Tacke, et al. The Randomized Freeway Stent Study: Drug-Eluting Balloons Outperform Standard Balloon Angioplasty for Postdilatation of Nitinol Stents in the SFA and PI Segment
- Open Access
- 20 August 2019
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 42 (11) , 1513-1521
The Randomized Freeway Stent Study: Drug-Eluting Balloons Outperform Standard Balloon Angioplasty for Postdilatation of Nitinol Stents in the SFA and PI Segment
Purpose The prospective randomized multicenter Freeway study evaluated the possible hemodynamic and clinical benefits of primary stent insertion followed by percutaneous transluminal angioplasty (PTA) with drug-eluting balloons (DEB) over post-stent insertion PTA with standard balloons in the treatment of symptomatic femoropopliteal arteriosclerotic lesions. Methods In total, 204 patients in 13 centers in Germany and Austria were enrolled and randomized to primary stenting followed by either FREEWAY™ drug-eluting balloon or standard PTA balloon angioplasty. The primary endpoint was the rate of clinically driven target lesion revascularization (TLR) at 6 months; the secondary endpoints include TLR rate at 12 months and primary patency, shift in Rutherford classification, ankle–brachial index (ABI) and major adverse events (MAE) at 6 and 12 months. Lesion characteristics and vessel patency were analyzed by an independent and blinded corelab. Results At 6-month and 12-month follow-up, TLR rate was lower in the DEB arm compared to standard PTA but did not reach statistical significance (4.1% vs. 9.0% p = 0.234 and 7.9% vs. 17.7% p = 0.064, respectively). Primary patency was significantly better for patients treated with the DEB at 6 months (90.3% vs. 69.8% p = 0.001) and 12 months (77.4% vs. 61.0% p = 0.027). Improvement in Rutherford classifications was likewise significantly better for patients in the DEB group at 6 (94.9% vs. 84.3% p = 0.027) and 12 months (95.5% vs. 79.9% p = 0.003). The percentage of patients with an improved ABI of 1.0–1.2 was significantly higher in the DEB group compared to the PTA group at 6 months (55.3% vs. 35.3%; p = 0.015) but without significant difference at 12 months (48.2% vs. 32.9%; p = 0.055). At 6 months, rate of major adverse events (MAE) was 1% in both arms, and at 12 months 2.2% for the DEB and 3.8% for the PTA group. Conclusion The Freeway Stent Study shows that the usage of DEB as a restenosis prophylaxis seems to be safe and feasible. The 12-month follow-up results give a clear sign in favor of the DEB group.
- 20 August 2019
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 42 (11) , 1513-1521
Open AccessThe Randomized Freeway Stent Study: Drug-Eluting Balloons Outperform Standard Balloon Angioplasty for Postdilatation of Nitinol Stents in the SFA and PI Segment
Purpose The prospective randomized multicenter Freeway study evaluated the possible hemodynamic and clinical benefits of primary stent insertion followed by percutaneous transluminal angioplasty (PTA) with drug-eluting balloons (DEB) over post-stent insertion PTA with standard balloons in the treatment of symptomatic femoropopliteal arteriosclerotic lesions. Methods In total, 204 patients in 13 centers in Germany and Austria were enrolled and randomized to primary stenting followed by either FREEWAY™ drug-eluting balloon or standard PTA balloon angioplasty. The primary endpoint was the rate of clinically driven target lesion revascularization (TLR) at 6 months; the secondary endpoints include TLR rate at 12 months and primary patency, shift in Rutherford classification, ankle–brachial index (ABI) and major adverse events (MAE) at 6 and 12 months. Lesion characteristics and vessel patency were analyzed by an independent and blinded corelab. Results At 6-month and 12-month follow-up, TLR rate was lower in the DEB arm compared to standard PTA but did not reach statistical significance (4.1% vs. 9.0% p = 0.234 and 7.9% vs. 17.7% p = 0.064, respectively). Primary patency was significantly better for patients treated with the DEB at 6 months (90.3% vs. 69.8% p = 0.001) and 12 months (77.4% vs. 61.0% p = 0.027). Improvement in Rutherford classifications was likewise significantly better for patients in the DEB group at 6 (94.9% vs. 84.3% p = 0.027) and 12 months (95.5% vs. 79.9% p = 0.003). The percentage of patients with an improved ABI of 1.0–1.2 was significantly higher in the DEB group compared to the PTA group at 6 months (55.3% vs. 35.3%; p = 0.015) but without significant difference at 12 months (48.2% vs. 32.9%; p = 0.055). At 6 months, rate of major adverse events (MAE) was 1% in both arms, and at 12 months 2.2% for the DEB and 3.8% for the PTA group. Conclusion The Freeway Stent Study shows that the usage of DEB as a restenosis prophylaxis seems to be safe and feasible. The 12-month follow-up results give a clear sign in favor of the DEB group.
- 1 October 2013
- Published by International Society of Endovascular Specialists in Journal of Endovascular Therapy
- Vol. 20 (5) , 609-618
Endovascular Treatment of Delayed Rupture Following Prior Abdominal Aortic Aneurysm Repair Achieves Better Survival Rates
Purpose To test the hypothesis that endovascular treatment of delayed aneurysm rupture achieves significantly better survival rates compared to surgical conversion. Methods All patients sustaining delayed rupture following prior exclusion of an abdominal aortic aneurysm (AAA) either by endovascular aneurysm repair (EVAR) or open graft replacement from March 1995 through December 2011 were retrieved from a prospectively maintained database at a tertiary care university hospital. During the study period, 35 patients (32 men; mean age 72.9 years) presented with delayed rupture at a median 2.4 years (interquartile range 1.3–4.3) after initial AAA repair by EVAR (n=22) or open surgery (n=13). Causes of post-EVAR rupture were graft-related endoleaks, while ruptures after open repair occurred at anastomotic suture sites. Patients were divided into groups regarding type of treatment for delayed rupture: 20/35 (57%) underwent successful EVAR (10 redo procedures), 13/35 (37%) had surgery (3 redo procedures), and 2/35 (6%) patients received comfort care only. The primary endpoint was 30-day mortality. Results The 30-day mortality after curative treatment was 25% (5/20) for endovascular treatment compared to 54% (7/13) for surgery (p=0.14). Including additional deaths beyond 30 days, the overall in-hospital mortality was 52% (17/33). The Kaplan-Meier survival estimate for patients undergoing endovascular treatment was significantly higher (p=0.011). Conclusion Endovascular treatment of delayed rupture is feasible and helps to reduce mortality. Our data suggest that endovascular procedures are a superior treatment option for EVAR-suitable patients with delayed rupture compared with surgical conversion.
- 1 October 2013
- Published by International Society of Endovascular Specialists in Journal of Endovascular Therapy
- Vol. 20 (5) , 609-618
Endovascular Treatment of Delayed Rupture Following Prior Abdominal Aortic Aneurysm Repair Achieves Better Survival Rates
Purpose To test the hypothesis that endovascular treatment of delayed aneurysm rupture achieves significantly better survival rates compared to surgical conversion. Methods All patients sustaining delayed rupture following prior exclusion of an abdominal aortic aneurysm (AAA) either by endovascular aneurysm repair (EVAR) or open graft replacement from March 1995 through December 2011 were retrieved from a prospectively maintained database at a tertiary care university hospital. During the study period, 35 patients (32 men; mean age 72.9 years) presented with delayed rupture at a median 2.4 years (interquartile range 1.3–4.3) after initial AAA repair by EVAR (n=22) or open surgery (n=13). Causes of post-EVAR rupture were graft-related endoleaks, while ruptures after open repair occurred at anastomotic suture sites. Patients were divided into groups regarding type of treatment for delayed rupture: 20/35 (57%) underwent successful EVAR (10 redo procedures), 13/35 (37%) had surgery (3 redo procedures), and 2/35 (6%) patients received comfort care only. The primary endpoint was 30-day mortality. Results The 30-day mortality after curative treatment was 25% (5/20) for endovascular treatment compared to 54% (7/13) for surgery (p=0.14). Including additional deaths beyond 30 days, the overall in-hospital mortality was 52% (17/33). The Kaplan-Meier survival estimate for patients undergoing endovascular treatment was significantly higher (p=0.011). Conclusion Endovascular treatment of delayed rupture is feasible and helps to reduce mortality. Our data suggest that endovascular procedures are a superior treatment option for EVAR-suitable patients with delayed rupture compared with surgical conversion.
- Top Cited Papers
Heparin-Bonded Covered Stents Versus Bare-Metal Stents for Complex Femoropopliteal Artery Lesions
- Open Access
- 18 September 2013
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 17 (suppl 2) , S118
202 * AORTIC ARCH REROUTING FOLLOWED BY THORACIC ENDOVASCULAR STENT GRAFT IMPLANTATION: A WORD OF CAUTION
Objectives: To assess the short- and mid-term results of supra-aortic arch rerouting procedures (SAARP) after thoracic endovascular stent graft implantation (TEVAR). Methods: From 1996 to 2012, 90 patients, median age 71 years (30% female) with aortic arch pathologies (aortic aneurysm n = 59, type B aortic dissection n = 13, perforating ulcer n = 15, acute traumatic lesions n = 3) underwent SAARP and subsequently TEVAR. The operative strategy for arch rerouting was subclavian-to-carotid transposition (STCT) in 24 patients, double transposition (DT) in 50 patients and total arch rerouting (TAR) in the remaining 16 patients. Results: Overall hospital mortality was 7% with no difference between the three rerouting strategies. Three patients developed a retrograde type A dissection after TEVAR, of whom one died. Early, as well secondary, endoleaks occurred in 27% and 4%, respectively. New permanent neurological dysfunctions were observed in five patients (4.5%) with the highest incidence in the TAR group (12.5%). Overall one-, three- and five-year survival was 79%, 66% and 60%, with the highest survival in the STCT group compared to the other two rerouting strategies (88%, 75%, 71% vs 76%, 63% and 56% at one, three and five years). Conclusions: Supra-aortic transposition combined with TEVAR is feasible with an acceptable hospital mortality but high rates of primary endoleaks. Mid-term results are only acceptable in the STCT group. More complex arch rerouting procedures revealed impaired mid-term survival and high rates of neurological deficit. It remains questionable whether SAARP followed by TEVAR is superior to conventional aortic surgery.
- 18 September 2013
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 17 (suppl 2) , S118
Open Access202 * AORTIC ARCH REROUTING FOLLOWED BY THORACIC ENDOVASCULAR STENT GRAFT IMPLANTATION: A WORD OF CAUTION
Objectives: To assess the short- and mid-term results of supra-aortic arch rerouting procedures (SAARP) after thoracic endovascular stent graft implantation (TEVAR). Methods: From 1996 to 2012, 90 patients, median age 71 years (30% female) with aortic arch pathologies (aortic aneurysm n = 59, type B aortic dissection n = 13, perforating ulcer n = 15, acute traumatic lesions n = 3) underwent SAARP and subsequently TEVAR. The operative strategy for arch rerouting was subclavian-to-carotid transposition (STCT) in 24 patients, double transposition (DT) in 50 patients and total arch rerouting (TAR) in the remaining 16 patients. Results: Overall hospital mortality was 7% with no difference between the three rerouting strategies. Three patients developed a retrograde type A dissection after TEVAR, of whom one died. Early, as well secondary, endoleaks occurred in 27% and 4%, respectively. New permanent neurological dysfunctions were observed in five patients (4.5%) with the highest incidence in the TAR group (12.5%). Overall one-, three- and five-year survival was 79%, 66% and 60%, with the highest survival in the STCT group compared to the other two rerouting strategies (88%, 75%, 71% vs 76%, 63% and 56% at one, three and five years). Conclusions: Supra-aortic transposition combined with TEVAR is feasible with an acceptable hospital mortality but high rates of primary endoleaks. Mid-term results are only acceptable in the STCT group. More complex arch rerouting procedures revealed impaired mid-term survival and high rates of neurological deficit. It remains questionable whether SAARP followed by TEVAR is superior to conventional aortic surgery.
- 23 January 2013
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 61 (S 01) , OP42
Supra-aortic transposition prior to endovascular stent implantation in the treatment of aortic arch pathologies
Objective: Combined transposition of the supra-aortal branches and endovascular stent graft implantation are now established methods in the treatment of several pathologies of the aortic arch. Post interventional outcome needs to be determined. Methods: From 1996 through Nov 2011 91 patient, median age 71 years (67% male,) with several aortic arch pathologies (degenerative aortic aneurysm n = 59, type B aortic dissections n = 13, perforating ulcer n = 16, acute traumatic lesions n = 3) underwent the combined treatment of supra-aortal transposition and subsequently endovascular stent graft implantation. Operative strategy for distal arch pathologies was subclavian-to-carotid transposition (n = 24) or double vessel transposition (n = 51). Total supra-aortic rerouting (n = 16) was performed by using a reversed bifurcated prosthesis. Endovascular stent graft implantation was applied consecutively. Results: The 30 day mortality was 7% (n = 6). Overall rate of early endoleak was 24% (n = 22) and late endoleak rate was 5%. Mean follow-up was 46 months with an overall survival of 88%, 64% and 45% after 1, 3 and 5 years. Conclusion: Transposition of the supra-aortic branches, combined with endovascular stent implantation for treatment of various aortic arch pathologies is a promising approach with acceptable results. Further outcome improvement could be achieved by analyzing the long term morbidity and appearance of serious adverse events related to the intervention on the aortic arch.
- 23 January 2013
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 61 (S 01) , OP42
Supra-aortic transposition prior to endovascular stent implantation in the treatment of aortic arch pathologies
Objective: Combined transposition of the supra-aortal branches and endovascular stent graft implantation are now established methods in the treatment of several pathologies of the aortic arch. Post interventional outcome needs to be determined. Methods: From 1996 through Nov 2011 91 patient, median age 71 years (67% male,) with several aortic arch pathologies (degenerative aortic aneurysm n = 59, type B aortic dissections n = 13, perforating ulcer n = 16, acute traumatic lesions n = 3) underwent the combined treatment of supra-aortal transposition and subsequently endovascular stent graft implantation. Operative strategy for distal arch pathologies was subclavian-to-carotid transposition (n = 24) or double vessel transposition (n = 51). Total supra-aortic rerouting (n = 16) was performed by using a reversed bifurcated prosthesis. Endovascular stent graft implantation was applied consecutively. Results: The 30 day mortality was 7% (n = 6). Overall rate of early endoleak was 24% (n = 22) and late endoleak rate was 5%. Mean follow-up was 46 months with an overall survival of 88%, 64% and 45% after 1, 3 and 5 years. Conclusion: Transposition of the supra-aortic branches, combined with endovascular stent implantation for treatment of various aortic arch pathologies is a promising approach with acceptable results. Further outcome improvement could be achieved by analyzing the long term morbidity and appearance of serious adverse events related to the intervention on the aortic arch.
- 1 September 2012
- Published by Elsevier in European Journal of Radiology
- Vol. 81 (9) , 2265-2269
Agreement of duplex ultrasonography vs. computed tomography angiography for evaluation of native and in-stent SFA re-stenosis—Findings from a randomized controlled trial
- 1 September 2012
- Published by Elsevier in European Journal of Radiology
- Vol. 81 (9) , 2265-2269
Agreement of duplex ultrasonography vs. computed tomography angiography for evaluation of native and in-stent SFA re-stenosis—Findings from a randomized controlled trial
- 28 August 2012
- Published by Georg Thieme Verlag KG in RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
- Vol. 183 (08) , V1_02
Bildqualität und Strahlendosis eines Niedrigdosis Dual Source CT-Angiografie Protokolls der supraaortalen Gefäße unter Verwendung von niedrigem Röhrenstrom, erhöhten Tischvorschub und iterativer Rekonstruktionsalgorithmen - vorläufige Ergebnisse
Problemstellung: Die Zielsetzung dieser prospektiven Studie war der Vergleich von Bildqualität und Strahlendosis eines Niedrigdosis Dual Source CT-Angiografie Protokolls der supraaortalen Gefäßäste unter der Verwendung von erniedrigter Röhrenspannung, eines stark erhöhten Tischvorschubes und iterativen Rekonstruktionsalgorithmen im Vergleich zu einem Standard Dual Source CT-Angiografie Protokolls. Patienten und Methoden: 20 Patienten mit suszipierten Pathologien der supraaortalen Gefäßäste wurden in diese prospektive Studie eingeschlossen. Die CT-Angiografie wurde entweder mit 100kV Röhrenspannung, einem Pitch von 3,2 und rohdatenbasierter iterativer Bildrekonstruktion, oder mit 120kV Röhrenspannung, einem Pitch von 2,4 und gefilterter Rückprojektion durchgeführt. Hintergrundrauschen, das Kontrast/Rausch sowie das Signal/Rausch Verhältnis wurde zum Vergleich der objektiven Bildqualität jeweils in 7 Gefäßsegmenten berechnet. Für den Gruppenvergleich der subjektiven Bildqualität wurde eine 4 Punkte Skala (nicht diagnostisch bis optimal) für jeweils 15 Gefäßsegmente angewandt. Das Dosis-Längen-Produkt (DLP) wurde für den Vergleich der Strahlendosis herangezogen. Ergebnisse: Die Verwendung von 100kV Röhrenspannung, eines maximal erhöhten Tischvorschubes sowie iterativer Rekonstruktionsalgorithmen zeigte eine nichtsignifikant höhere Gefäßkontrastierung (p=0,07) und reduziertes Hintergrundrauschen in allen Gefäßsegmenten (p=0,381) was weiterführend, verglichen mit dem Standard-Protokoll, in nichtsignifikant höheren Kontrast/Rausch (p=0,159) und Signal/Rausch Verhältnis (p=0,152) Werten in allen Gefäßsegmenten resultierte. Die Auswertung der subjektiven Bildqualität zeigt keinen Unterschied zwischen den CT-Angiografie Studienprotokollen. Die DLP Werte waren hochsignifikant niedriger in der 100kV-Studiengruppe (90,6±7,9 vs. 228,3±38,3 mGy*cm; pSchlussfolgerung: Die vorläufigen Daten dieser Studie zeigen, dass die Strahlendosis einer Dual Source CT-Angiografie der supraaortalen Gefäßäste mittels der Anwendung von 100kV Röhrenspannung kombiniert mit einem maximalen Tischvorschub und rohdatenbasierter iterativer Rekonstruktionsalgorithmen um 60% reduziert werden kann, ohne die diagnostische Bildqualität zu beeinflussen.
- 28 August 2012
- Published by Georg Thieme Verlag KG in RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
- Vol. 183 (08) , V1_02
Bildqualität und Strahlendosis eines Niedrigdosis Dual Source CT-Angiografie Protokolls der supraaortalen Gefäße unter Verwendung von niedrigem Röhrenstrom, erhöhten Tischvorschub und iterativer Rekonstruktionsalgorithmen - vorläufige Ergebnisse
Problemstellung: Die Zielsetzung dieser prospektiven Studie war der Vergleich von Bildqualität und Strahlendosis eines Niedrigdosis Dual Source CT-Angiografie Protokolls der supraaortalen Gefäßäste unter der Verwendung von erniedrigter Röhrenspannung, eines stark erhöhten Tischvorschubes und iterativen Rekonstruktionsalgorithmen im Vergleich zu einem Standard Dual Source CT-Angiografie Protokolls. Patienten und Methoden: 20 Patienten mit suszipierten Pathologien der supraaortalen Gefäßäste wurden in diese prospektive Studie eingeschlossen. Die CT-Angiografie wurde entweder mit 100kV Röhrenspannung, einem Pitch von 3,2 und rohdatenbasierter iterativer Bildrekonstruktion, oder mit 120kV Röhrenspannung, einem Pitch von 2,4 und gefilterter Rückprojektion durchgeführt. Hintergrundrauschen, das Kontrast/Rausch sowie das Signal/Rausch Verhältnis wurde zum Vergleich der objektiven Bildqualität jeweils in 7 Gefäßsegmenten berechnet. Für den Gruppenvergleich der subjektiven Bildqualität wurde eine 4 Punkte Skala (nicht diagnostisch bis optimal) für jeweils 15 Gefäßsegmente angewandt. Das Dosis-Längen-Produkt (DLP) wurde für den Vergleich der Strahlendosis herangezogen. Ergebnisse: Die Verwendung von 100kV Röhrenspannung, eines maximal erhöhten Tischvorschubes sowie iterativer Rekonstruktionsalgorithmen zeigte eine nichtsignifikant höhere Gefäßkontrastierung (p=0,07) und reduziertes Hintergrundrauschen in allen Gefäßsegmenten (p=0,381) was weiterführend, verglichen mit dem Standard-Protokoll, in nichtsignifikant höheren Kontrast/Rausch (p=0,159) und Signal/Rausch Verhältnis (p=0,152) Werten in allen Gefäßsegmenten resultierte. Die Auswertung der subjektiven Bildqualität zeigt keinen Unterschied zwischen den CT-Angiografie Studienprotokollen. Die DLP Werte waren hochsignifikant niedriger in der 100kV-Studiengruppe (90,6±7,9 vs. 228,3±38,3 mGy*cm; pSchlussfolgerung: Die vorläufigen Daten dieser Studie zeigen, dass die Strahlendosis einer Dual Source CT-Angiografie der supraaortalen Gefäßäste mittels der Anwendung von 100kV Röhrenspannung kombiniert mit einem maximalen Tischvorschub und rohdatenbasierter iterativer Rekonstruktionsalgorithmen um 60% reduziert werden kann, ohne die diagnostische Bildqualität zu beeinflussen.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , e14660
Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: Results from the PRECISION V randomized trial.
E14660 Background: To evaluate the toxicity focussing on hepatic, gastrointestinal and cardiac parameters following PRECISION TACE with DC Bead versus conventional transarterial chemoembolization (cTACE) in the treatment of intermediate-stage hepatocellular carcinoma (HCC). Methods: This prospective, randomized, multicenter study was conducted under best practice trial management and authorized by local institutional review boards. Informed consent was obtained. 212 patients (185 men/27 women; mean: 67 years) were randomized to be treated with DC Beads or cTACE. The majority of both groups presented in a more advanced stage. Safety was measured by rate of adverse events (South West Oncology Group criteria) and changes in laboratory parameters. Cardiotoxicity was assessed by means of left ventricular ejection fraction (LVEF) in MRI or echocardiography. Results of the two groups were compared using the chi-square test and Student's t-test. Mean maximum alanine transaminase increase in the DC Bead group was 50% in the cTACE group (p<0.001) and 59% for aspartate transaminase (p<0.001). For bilirubin, mean increase was 5.30±15.13 vs. 13.53±73.89μmol/L. Concerning gastrointestinal disorders 120 adverse events (AEs) occurred in 57/93 (61.3%) patients in the DC Bead group vs. 114 in 49/108 (45.4%) in cTACE. Concerning hepatobiliary disorders serious AEs occurred in 8/93 (8.6%) vs. 11/108 (10.2%) patients. LVEF showed an increase in the DC Bead group by +2.7±10.1 percentage points and a small decrease by -1.5±7.6 in the cTACE group, p=0.018. PRECISION TACE is safe, even in more advanced HCC patients. Serious liver and cardiac toxicity were significantly lower in the DC Bead group. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , e14660
Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: Results from the PRECISION V randomized trial.
E14660 Background: To evaluate the toxicity focussing on hepatic, gastrointestinal and cardiac parameters following PRECISION TACE with DC Bead versus conventional transarterial chemoembolization (cTACE) in the treatment of intermediate-stage hepatocellular carcinoma (HCC). Methods: This prospective, randomized, multicenter study was conducted under best practice trial management and authorized by local institutional review boards. Informed consent was obtained. 212 patients (185 men/27 women; mean: 67 years) were randomized to be treated with DC Beads or cTACE. The majority of both groups presented in a more advanced stage. Safety was measured by rate of adverse events (South West Oncology Group criteria) and changes in laboratory parameters. Cardiotoxicity was assessed by means of left ventricular ejection fraction (LVEF) in MRI or echocardiography. Results of the two groups were compared using the chi-square test and Student's t-test. Mean maximum alanine transaminase increase in the DC Bead group was 50% in the cTACE group (p<0.001) and 59% for aspartate transaminase (p<0.001). For bilirubin, mean increase was 5.30±15.13 vs. 13.53±73.89μmol/L. Concerning gastrointestinal disorders 120 adverse events (AEs) occurred in 57/93 (61.3%) patients in the DC Bead group vs. 114 in 49/108 (45.4%) in cTACE. Concerning hepatobiliary disorders serious AEs occurred in 8/93 (8.6%) vs. 11/108 (10.2%) patients. LVEF showed an increase in the DC Bead group by +2.7±10.1 percentage points and a small decrease by -1.5±7.6 in the cTACE group, p=0.018. PRECISION TACE is safe, even in more advanced HCC patients. Serious liver and cardiac toxicity were significantly lower in the DC Bead group. No significant financial relationships to disclose.